Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active‐controlled, randomized, double‐blind study with open‐label extension (the EVERGREEN study)
Kim, Gyuri, Lim, Soo, Kwon, Hyuk‐Sang, Park, Ie B., Ahn, Kyu J., Park, Cheol‐Young, Kwon, Su K., Kim, Hye S., Park, Seok W., Kim, Sin G., Moon, Min K., Kim, Eun S., Chung, Choon H., Park, Kang S., Kim, Mikyung, Chung, Dong J., Lee, Chang B., Kim, Tae H., Lee, Moon‐Kyu
Published in Diabetes, obesity & metabolism (01.09.2020)
Published in Diabetes, obesity & metabolism (01.09.2020)
Get full text
Journal Article
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
Seino, Y., Min, K. W., Niemoeller, E., Takami, A.
Published in Diabetes, obesity & metabolism (01.10.2012)
Published in Diabetes, obesity & metabolism (01.10.2012)
Get full text
Journal Article